# INCB38579

®

MedChemExpress

Cat. No.:	HY-101188		
CAS No.:	1246207-65-	7	
Molecular Formula:	$C_{25}H_{34}N_6O$		
Molecular Weight:	434.58		
Target:	Histamine R	eceptor	
Pathway:	GPCR/G Prot	tein; Imm	unology/Inflammation; Neuronal Signaling
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

### SOLVENT & SOLUBILITY

	Solvent Mass Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	2.3011 mL	11.5054 mL	23.0107 mL
	5 mM	0.4602 mL	2.3011 mL	4.6021 mL	
	10 mM	0.2301 mL	1.1505 mL	2.3011 mL	

BIOLOGICAL ACTIV			
BIOLOGICALINGIN			
Description	INCB38579 is an orally active, nM, mH <sub>4</sub> R IC <sub>50</sub> =42 nM, rH <sub>4</sub> R IC	highly brain penetrable, and sele C <sub>50</sub> =32 nM). INCB38579 shows an	ective histamine H <sub>4</sub> receptor (HH <sub>4</sub> R) antagonist (hH <sub>4</sub> R IC <sub>50</sub> =4.8 ti-inflammatory pain and anti-pruritic activities <sup>[1]</sup> .
IC <sub>50</sub> & Target	Human H <sub>4</sub> Receptor 4.8 nM (IC <sub>50</sub> )	Mouse H <sub>4</sub> Receptor 42 nM (IC <sub>50</sub> )	Rat H <sub>4</sub> receptor 21 nM (IC <sub>50</sub> )
In Vitro	INCB38579 (0.1 nM-10 μM; 1.5 INCB38579 (0.1 nM-10 μM; 20 monocytes and mouse bone r NCB38579 (0-30 nM; 1.5 h) inh dependently <sup>[1]</sup> . MCE has not independently co Cell Viability Assay <sup>[1]</sup>	h) inhibits histamine binding to min) blocks histamine-induced n marrow cells <sup>[1]</sup> . Nibits histamine-induced cell shap	the recombinant human and rodent histamine H <sub>4</sub> receptors <sup>[1]</sup> . nigration of dendritic cells differentiated from human be change and migration of purified human eosinophils dose- nethods. They are for reference only.

0

Cell Line:	HEK293 cells
Concentration:	0.1 nM-10 μM
Incubation Time:	1.5 hours
Result:	Showed the IC $_{\rm 50}$ values of 4.8, 42 and 21 nM for the human, mouse and rat histamine $\rm H_4$ receptors, respectively.

### Cell Viability Assay<sup>[1]</sup>

Cell Line:	Human monocytes, mouse bone marrow cells, and human eosinophils
Concentration:	0.1 nM-10 μM
Incubation Time:	20 min
Result:	Showed IC <sub>50</sub> s of 13.2 and 77 nM for human monocytes and mouse bone marrow cells respectively. Showed IC <sub>50</sub> values of approximately 20-30 nM for purified human eosinophils.

## Cell Viability Assay<sup>[1]</sup>

Cell Line:	HEK293 cells
Concentration:	0-30 nM
Incubation Time:	1.5 hours
Result:	Showed the IC $_{\rm 50}$ values of 4.8, 42 and 21 nM for the human, mouse and rat histamine $\rm H_4$ receptors, respectively.

#### In Vivo

INCB38579 (oral gavage; 100 mg/kg; once) inhibits histamine-mediated pruritus in mice<sup>[1]</sup>.
INCB38579 (oral gavage; 100 mg/kg; once) shows antinociceptive functions in this acute model of inflammatory pain<sup>[1]</sup>.
INCB38579 (oral gavage; 3, 10, 30, and 100 mg/kg; once) inhibits formalin-induced pain in rats and mice<sup>[1]</sup>.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female CD-1 mice histamine-induced pruritus <sup>[1]</sup>
Dosage:	100 mg/kg
Administration:	Oral gavage; 100 mg/kg; once
Result:	Reduced the number of scratching bouts significantly (P<0.05).

Animal Model:	Sprague-Dawley rats injected with carrageenan <sup>[1]</sup>
Dosage:	100 mg/kg
Administration:	Oral gavage; 100 mg/kg; once
Result:	Increased the paw withdrawal threshold from a baseline of 61 g to approximately 100 g, achieving approximately 60% in maximal possible effect.
Animal Model:	Male Sprague–Dawley rats and male ICR mice injected with formalin into the hind $paws^{[1]}$

Dosage:	3, 10, 30, and 100 mg/kg
Administration:	Oral gavage; 3, 10, 30, and 100 mg/kg; once
Result:	Showed a significant dose-dependent analgesic effect from 10 to 100 mg/kg in the phase response and 30 to 100 mg/kg in the phase 2 response in the mouse formalin test. Observed a dose-dependent and statistically significant effect in the phase 1 response, ranging from10 to 100 mg/kg, in the rat formalin test.

### REFERENCES

[1]. Niu Shin, et al. INCB38579, a novel and potent histamine H<sub>4</sub> receptor small molecule antagonist with anti-inflammatory pain and anti-pruritic functions. Eur J Pharmacol. 2012 Jan 30;675(1-3):47-56.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA